[1]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548.
https://doi.org/10.1016/S1470-2045(14)70442-5
|
[2]
|
张之尧, 陈文明. 多发性骨髓瘤骨病的诊断进展[J]. 实用肿瘤杂志, 2018, 33(5): 402-406.
|
[3]
|
Edelstyn, G.A., Gillespie, P.J. and Grebbell, F.S. (1967) The Radiological Demonstration of Osseous Metastases. Experimental Observations. Clinical Radiology, 18, 158-162. https://doi.org/10.1016/S0009-9260(67)80010-2
|
[4]
|
Pianko, M.J., Terpos, E., Roodman, G.D., et al. (2014) Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease. Clinical Cancer Research, 20, 5888-5897.
https://doi.org/10.1158/1078-0432.CCR-14-1692
|
[5]
|
Ippolito, D., Besostri, V., Bonaffini, P.A., et al. (2013) Diagnostic Value of Whole-Body Low-Dose Computed Tomography (WBLDCT) in Bone Lesions Detection in Patients with Multiple Myeloma (MM). European Journal of Radiology, 82, 2322-2327. https://doi.org/10.1016/j.ejrad.2013.08.036
|
[6]
|
Horger, M., Claussen, C.D., Bross-Bach, U., et al. (2005) Whole-Body Low-Dose Multidetector Row-CT in the Diagnosis of Multiple Myeloma: An Alternative to Conventional Radiography. European Journal of Radiology, 54, 289-297.
https://doi.org/10.1016/j.ejrad.2004.04.015
|
[7]
|
Kröpil, P., Fenk, R., Fritz, L.B., et al. (2008) Comparison of Whole-Body 64-Slice Multidetector Computed Tomography and Conventional Radiography in Staging of Multiple Myeloma. European Radiology, 18, 51-58.
https://doi.org/10.1007/s00330-007-0738-3
|
[8]
|
Wolf, M.B., Murray, F., Kilk, K., et al. (2014) Sensitivity of Whole-Body CT and MRI versus Projection Radiography in the Detection of Osteolyses in Patients with Monoclonal Plasma Cell Disease. European Journal of Radiology, 83, 1222-1230. https://doi.org/10.1016/j.ejrad.2014.02.008
|
[9]
|
Hillengass, J., Moulopoulos, L.A., Delorme, S., et al. (2017) Whole-Body Computed Tomography versus Conventional Skeletal Survey in Patients with Multiple Myeloma: A Study of the International Myeloma Working Group. Blood Cancer Journal, 7, e599. https://doi.org/10.1038/bcj.2017.78
|
[10]
|
Kosmala, A., Weng, A.M., Heidemeier, A., et al. (2018) Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis. Radiology, 286, 205-213. https://doi.org/10.1148/radiol.2017170281
|
[11]
|
Cascini, G.L., Falcone, C., Console, D., et al. (2013) Whole-Body MRI and PET/CT in Multiple Myeloma Patients during Staging and after Treatment: Personal Experience in a Longitudinal Study. La Radiologia Medica, 118, 930-948.
https://doi.org/10.1007/s11547-013-0946-7
|
[12]
|
Shortt, C.P., Gleeson, T.G., Breen, K.A., et al. (2009) Whole-Body MRI versus PET in Assessment of Multiple Myeloma Disease Activity. AJR. American Journal of Roentgenology, 192, 980-986. https://doi.org/10.2214/AJR.08.1633
|
[13]
|
Dutoit, J.C. and Verstraete, K.L. (2017) Whole-Body MRI, Dynamic Contrast-Enhanced MRI, and Diffusion-Weighted Imaging for the Staging of Multiple Myeloma. Skeletal Radiology, 46, 733-750.
https://doi.org/10.1007/s00256-017-2609-6
|
[14]
|
Lu, Y.Y., Chen, J.H., Lin, W.Y., et al. (2012) FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-Analysis. Clinical Nuclear Medicine, 37, 833-837.
https://doi.org/10.1097/RLU.0b013e31825b2071
|
[15]
|
Adam, Z., Bolcak, K., Stanicek, J., et al. (2007) Fluorodeoxyglucose Positron Emission Tomography in Multiple Myeloma, Solitary Plasmocytoma and Monoclonal Gammapathy of Unknown Significance. Neoplasma, 54, 536-540.
|
[16]
|
Zamagni, E., Patriarca, F., Nanni, C., et al. (2011) Prognostic Relevance of 18-F FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients Treated with Up-Front Autologous Transplantation. Blood, 118, 5989-5995.
https://doi.org/10.1182/blood-2011-06-361386
|
[17]
|
Bartel, T.B., Haessler, J., Brown, T.L., et al. (2009) F18-Fluorodeoxyglucose Positron Emission Tomography in the Context of Other Imaging Techniques and Prognostic Factors in Multiple Myeloma. Blood, 114, 2068-2076.
https://doi.org/10.1182/blood-2009-03-213280
|
[18]
|
Nanni, C., Zamagni, E., Celli, M., et al. (2013) The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience with 77 Patients. Clinical Nuclear Medicine, 38, e74-e79. https://doi.org/10.1097/RLU.0b013e318266cee2
|
[19]
|
Dupuis, M.M. and Tuchman, S.A. (2016) Non-Secretory Multiple Myeloma: From Biology to Clinical Management. OncoTargets and Therapy, 9, 7583-7590. https://doi.org/10.2147/OTT.S122241
|
[20]
|
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., et al. (2017) Role of 18F-FDG PET/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group. The Lancet Oncology, 18, e206-e217.
https://doi.org/10.1016/S1470-2045(17)30189-4
|
[21]
|
Baur, A., Stäbler, A., Bartl, R., Lamerz, R. and Reiser, M. (1996) Infiltrationsmuster des Plasmozytoms in der Magnetresonanztomographie [Infiltration Patterns of Plasmacytomas in Magnetic Resonance Tomography]. RöFo, 164, 457-463. (In German) https://doi.org/10.1055/s-2007-1015689
|
[22]
|
Baur-Melnyk, A., Buhmann, S., Dürr, H.R. and Reiser, M. (2005) Role of MRI for the Diagnosis and Prognosis of Multiple Myeloma. European Journal of Radiology, 55, 56-63. https://doi.org/10.1016/j.ejrad.2005.01.017
|
[23]
|
Stäbler, A., Baur, A., Bartl, R., Munker, R., Lamerz, R. and Reiser, M.F. (1996) Contrast Enhancement and Quantitative Signal Analysis in MR Imaging of Multiple Myeloma: Assessment of Focal and Diffuse Growth Patterns in Marrow Correlated with Biopsies and Survival Rates. AJR. American Journal of Roentgenology, 167, 1029-1036.
https://doi.org/10.2214/ajr.167.4.8819407
|
[24]
|
Moulopoulos, L.A., Dimopoulos, M.A., Christoulas, D., et al. (2010) Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly Diagnosed Myeloma Treated with Novel Agents. Leukemia, 24, 1206-1212. https://doi.org/10.1038/leu.2010.70
|
[25]
|
Hillengass, J., Bäuerle, T., Bartl, R., et al. (2011) Diffusion-Weighted Imaging for Non-Invasive and Quantitative Monitoring of Bone Marrow Infiltration in Patients with Monoclonal Plasma Cell Disease: A Comparative Study with Histology. British Journal of Haematology, 153, 721-728. https://doi.org/10.1111/j.1365-2141.2011.08658.x
|
[26]
|
Hillengass, J., Ellert, E., Spira, E., et al. (2016) Comparison of Plasma Cell Infiltration in Random Samples of the Bone Marrow and Osteolyses Acquired by CT-Guided Biopsy in Patients with Symptomatic Multiple Myeloma. Journal of Clinical Oncology, 34, 8040. https://doi.org/10.1200/JCO.2016.34.15_suppl.8040
|
[27]
|
Huang, S.Y., Chen, B.B., Lu, H.Y., Lin, H.H., Wei, S.Y., Hsu, S.C. and Shih, T.T. (2012) Correlation among DCE-MRI Measurements of Bone Marrow Angiogenesis, Microvessel Density, and Extramedullary Disease in Patients with Multiple Myeloma. American Journal of Hematology, 87, 837-839. https://doi.org/10.1002/ajh.23256
|
[28]
|
Hillengass, J. and Landgren, O. (2013) Challenges and Opportunities of Novel Imaging Techniques in Monoclonal Plasma Cell Disorders: Imaging “Early Myeloma”. Leukemia & Lymphoma, 54, 1355-1363.
https://doi.org/10.3109/10428194.2012.740559
|
[29]
|
van Lammeren-Venema, D., Regelink, J.C., Riphagen, I.I., et al. (2012) 18F-Fluoro-Deoxyglucose Positron Emission Tomography in Assessment of Myeloma-Related Bone Disease: A Systematic Review. Cancer, 118, 1971-1981.
https://doi.org/10.1002/cncr.26467
|
[30]
|
Dimopoulos, M., Terpos, E., Comenzo, R.L., et al. (2009) International Myeloma Working Group Consensus Statement and Guidelines Regarding the Current Role of Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma. Leukemia, 23, 1545-1556. https://doi.org/10.1038/leu.2009.89
|
[31]
|
Vande Berg, B.C., Michaux, L., Lecouvet, F.E., et al. (1997) Nonmyelomatous Monoclonal Gammopathy: Correlation of Bone Marrow MR Images with Laboratory Findings and Spontaneous Clinical Outcome. Radiology, 202, 247-251.
https://doi.org/10.1148/radiology.202.1.8988218
|
[32]
|
Hillengass, J., Fechtner, K., Weber, M.A., et al. (2010) Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients with Asymptomatic Multiple Myeloma. Journal of Clinical Oncology, 28, 1606-1610. https://doi.org/10.1200/JCO.2009.25.5356
|
[33]
|
Hillengass, J., Weber, M.A., Kilk, K., Listl, K., et al. (2014) Prognostic Significance of Whole-Body MRI in Patients with Monoclonal Gammopathy of Undetermined Significance. Leukemia, 28, 174-178.
https://doi.org/10.1038/leu.2013.244
|
[34]
|
Merz, M., Hielscher, T., Wagner, B., et al. (2014) Predictive Value of Longitudinal Whole-Body Magnetic Resonance Imaging in Patients with Smoldering Multiple Myeloma. Leukemia, 28, 1902-1908.
https://doi.org/10.1038/leu.2014.75
|
[35]
|
Wu, C., Huang, J., Xu, W.B., et al. (2018) Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-Body Diffusion-Weighted MRI with Apparent Diffusion Coefficient: Preliminary Results from a Single-Center Study. Academic Radiology, 25, 904-914. https://doi.org/10.1016/j.acra.2017.12.008
|
[36]
|
Latifoltojar, A., Hall-Craggs, M., Bainbridge, A., et al. (2017) Whole-Body MRI Quantitative Biomarkers Are Associated Significantly with Treatment Response in Patients with Newly Diagnosed Symptomatic Multiple Myeloma Following Bortezomib Induction. European Radiology, 27, 5325-5336. https://doi.org/10.1007/s00330-017-4907-8
|
[37]
|
Daldrup-Link, H.E., Henning, T. and Link, T.M. (2007) MR Imaging of Therapy-Induced Changes of Bone Marrow. European Radiology, 17, 743-761. https://doi.org/10.1007/s00330-006-0404-1
|